Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers: Friend or foe?
Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers: Friend or foe?
复制标题
DOI：
10.1097/md.0000000000008802
复制
发表时间：
2017-11
期刊：
影响因子：
1.6
通讯作者：
Mircescu G
中科院分区：
文献类型：
--
作者：
Căpuşă C;Ştefan G;Stancu S;Lipan M;Tsur LD;Mircescu G
慢性代谢性酸中毒（MA）对慢性肾脏病（CKD）背景下心血管疾病（CVD）的影响在很大程度上是未知的。因此，我们旨在研究非透析CKD患者中的这种关系。这项横断面、单中心研究前瞻性入组了95例临床稳定的CKD患者（中位年龄61（58，65）岁，60%为男性，中位eGFR 27（22，32）mL/min）。 收集了CKD病因、CVD病史、CVD传统和非传统危险因素的数据。此外，还评估了亚临床CVD的标志物：内膜中层厚度（IMT）、腹主动脉钙化（Kauppila评分-AAC）、心踝血管指数（CAVI）、踝臂指数（ABI）、射血分数和室间隔厚度。使用血清碳酸氢盐临界值22 mEq/L，对MA（<22 mEq/L; 43例患者）和非MA（≥22 mEq/L; 52例患者）组进行比较。 血管性肾病（40%）、肾小管间质性肾病（24%）和肾小球性肾病（22%）是CKD的主要病因。23%的患者患有糖尿病，但只有5%的患者被认为患有糖尿病肾病。慢性MA患者eGFR较低（P <0.01），iPTH较高（P = 0.01），血清磷酸盐较高（P <0.01），血清胆固醇和甘油三酯升高（P = 0.04）。 慢性MA患者的ABI较高（P = 0.04），IMT较低（P = 0.03），CAVI（P = 0.05）和AAC（P = 0.03）。 使用ABI（临界值0.9）、CAVI（临界值9）、IMT（临界值0.1 cm）和AAC（临界值1）作为因变量，进行单独的二项逻辑回归模型。 MA用作自变量，并对iPTH、血清磷酸盐、eGFR、蛋白尿、胆固醇、甘油三酯、CVD评分进行校正。MA的缺失仅作为存在AAC的独立预测因素。总之，本研究显示MA对透析前CKD患者的血管钙化具有潜在的有利影响。因此，放宽血清碳酸氢盐目标的指南可能对血管钙化高风险的CKD患者有益。然而，我们应该始终考虑MA的负面影响。因此，在任何明确的临床建议之前，需要进行额外的研究。
The effect of chronic metabolic acidosis (MA) on cardiovascular disease (CVD) in the setting of chronic kidney disease (CKD) is largely unknown. Therefore, we aimed to study this relationship in nondialysis CKD patients. This cross-sectional, single-center study prospectively enrolled 95 clinically stable CKD patients (median age 61 (58, 65) years, 60% male, median eGFR 27 (22, 32) mL/min). Data on CKD etiology, CVD history, CVD traditional, and nontraditional risk factors were obtained. Also, markers of subclinical CVD were assessed: intima-media thickness (IMT), abdominal aortic calcifications (Kauppila score—AACs), cardio-ankle vascular index (CAVI), ankle-brachial index (ABI), ejection fraction, and interventricular septum thickness. Using the serum bicarbonate cutoff value of 22 mEq/L, comparisons between MA (<22 mEq/L; 43 patients) and non-MA (≥22 mEq/L; 52 patients) groups were performed. Vascular (40%), tubulointerstitial (24%), and glomerular (22%) nephropathies were the main causes of CKD. Twenty-three percent of patients had diabetes mellitus, but only 5% were considered to have diabetic nephropathy. Patients with chronic MA had lower eGFR (P < .01), higher iPTH (P = .01), higher serum phosphate (P < .01), and increased serum cholesterol (P = .04) and triglycerides (P = .01). Higher ABI (P = .04), lower IMT (P = .03), CAVI (P = .05), and AACs (P = .03) were found in patients with chronic MA. Separate binomial logistic regression models were performed using ABI (cutoff 0.9), CAVI (cutoff 9), IMT (cutoff 0.1 cm), and AACs (cutoff 1) as dependent variables. MA was used as independent variable and adjustments were made for iPTH, serum phosphate, eGFR, proteinuria, cholesterol, triglycerides, CVD score. The absence of MA was retained as an independent predictor only for the presence of AACs. In conclusion, the present study shows a potential advantageous effect of MA on vascular calcifications in predialysis CKD patients. Thus, a guideline relaxation of the serum bicarbonate target might prove to be beneficial in CKD patients at high risk of vascular calcifications. However, one should always consider the negative effects of MA. Therefore, additional research is warranted before any clear clinical recommendation.